Cargando…

Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data

Neu-glycolyl (NeuGc)-containing gangliosides are attractive targets for immunotherapy with anti-idiotype mAbs, because these glycolipids are not normal components of the cytoplasmic membrane in humans, but their expression has been demonstrated in several human malignant tumors. Racotumomab is an an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vázquez, Ana M., Hernández, Ana M., Macías, Amparo, Montero, Enrique, Gómez, Daniel E., Alonso, Daniel F., Gabri, Mariano R., Gómez, Roberto E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2012
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478665/ https://www.ncbi.nlm.nih.gov/pubmed/23110257 http://dx.doi.org/10.3389/fonc.2012.00150

Ejemplares similares

Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer
por: Segatori, Valeria I., et al.
Publicado: (2012)

Anti-idiotype antibodies in cancer treatment
por: Gomez, Daniel E., et al.
Publicado: (2013)

Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer
por: Scursoni, Alejandra M., et al.
Publicado: (2011)

Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines
por: Gabri, Mariano R, et al.
Publicado: (2009)

Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry
por: Vázquez, Ana M. H., et al.
Publicado: (2012)

Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System
por: Blanco, Rancés, et al.
Publicado: (2011)

Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy
por: Uskent, Necdet, et al.
Publicado: (2020)

NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines
por: Fernandez, Luis E., et al.
Publicado: (2010)

Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas
por: Pilco-Janeta, Daniel, et al.
Publicado: (2019)

Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer
por: Lahera, Tania, et al.
Publicado: (2014)

Immune response to racotumomab in a child with relapsed neuroblastoma
por: Sampor, C., et al.
Publicado: (2012)

Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3
por: Guthmann, Marcelo D., et al.
Publicado: (2013)

Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences
por: Blanco, Rancés, et al.
Publicado: (2015)

Tissue Reactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin
por: Blanco, Rancés, et al.
Publicado: (2013)

Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms
por: Blanco, Rancés, et al.
Publicado: (2011)

Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Primary Lymphoid Tumors and Lymph Node Metastasis
por: Blanco, Rancés, et al.
Publicado: (2013)

Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer
por: Blanco, Rancés, et al.
Publicado: (2012)

N-glycolyl chondroitin synthesis using metabolically engineered E. coli
por: Awofiranye, Adeola E., et al.
Publicado: (2020)

Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide
por: Coulombe, François, et al.
Publicado: (2009)

Behavior of glycolylated sialoglycans in the binding pockets of murine and human CD22
por: Di Carluccio, Cristina, et al.
Publicado: (2020)

Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma
por: Osorio, Marta, et al.
Publicado: (2012)

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
por: Soriano, Jorge L., et al.
Publicado: (2011)

Optimized Polyethylene Glycolylated Polymer–Lipid Hybrid Nanoparticles as a Potential Breast Cancer Treatment
por: Massadeh, Salam, et al.
Publicado: (2020)

Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective
por: Gómez, Roberto E., et al.
Publicado: (2012)

Idiotype-recognizing T helper cells that are not idiotype specific
Publicado: (1983)

Idiotypic regulation of the immune system. Common idiotypic specificities between idiotypes and antibodies raised against anti- idiotypic antibodies in rabbits
Publicado: (1979)

Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer
por: van Cruijsen, Hester, et al.
Publicado: (2009)

Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it’s potential therapeutic implications
por: Palomo, Addys González, et al.
Publicado: (2016)

Idiotype-anti-idiotype network. II. Activation of silent clones by treatment at birth with idiotypes is associated with the expansion of idiotype-specific helper T cells
Publicado: (1982)

Toward a fractalomic idiotype/anti-idiotypic paradigm
por: Chiappelli, Francesco, et al.
Publicado: (2022)

Suppression of idiotype and generation of suppressor T cells with idiotype-conjugated thymocytes
Publicado: (1979)

Deregulation of idiotype expression. Induction of tolerance in an anti- idiotypic response
Publicado: (1982)

Mechanisms of idiotype suppression. I. In vitro generation of idiotype- specific suppressor T cells by anti-idiotype antibodies and specific antigen
Publicado: (1979)

Selective suppression of the major idiotypic component of an antihapten response by soluble T cell-derived factors with idiotypic or anti- idiotypic receptors
Publicado: (1980)

Ganglioside synthase knockout in oncogene-transformed fibroblasts depletes gangliosides and impairs tumor growth
por: Liu, Yihui, et al.
Publicado: (2010)

Modification of T cell antinuclease idiotype expression by in vivo administration of anti-idiotype
Publicado: (1982)

Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3
por: Palomo, Addys González, et al.
Publicado: (2018)

Physicochemical and biological characterization of 1E10 Anti-Idiotype vaccine
por: Machado, Yoan J, et al.
Publicado: (2011)

Presence on idiotype-specific suppressor T cells of receptors that interact with molecules bearing the idiotype
Publicado: (1977)

Loss of an individual idiotype on chemical modification. A strategy for assigning idiotypic determinants
Publicado: (1981)

Cannot write session to /tmp/vufind_sessions/sess_ko42lf112i6e3lhf44543i8j9n